CTRI/2023/10/059200尚未招募2 期
MCS (MECHANIC, Cybernetic and Synergetic) protocol to improve dynamic balance and participation in patients with BPPV (Benign Paroxysmal Positional Vertigo) - nil
Dr. Divya pancholi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adults with vertigo symptoms who have undergone correction but shows residual symptoms which includes lightheadness /dizziness on movement.
排除标准
- •Any medical condition and injury that would hamper balance.
- •Any other co-existing neurological condition.
研究者
相似试验
招募中
不适用
Magneto-encephalography (MEG) to image the brain’s role in the analgesic effects of Spinal Cord Stimulation (SCS), an explorative studyNL-OMON26558Erasmus University Medical Centre25
招募中
1 期
ACP-204 in Adults with Alzheimer’s Disease PsychosisAlzheimer Disease psychosisMedDRA version: 20.0Level: PTClassification code: 10012271Term: Dementia Alzheimer's type Class: 100000004852CTIS2023-507325-42-00Acadia Pharmaceuticals Inc.1,074
进行中（未招募）
1 期
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-003690-21-RORegeneron Pharmaceuticals, Inc.1,368
进行中（未招募）
1 期
Safety, Tolerability, and Efficacy of Anti-Spike SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002537-15-RORegeneron Pharmaceuticals, Inc.2,970
进行中（未招募）
不适用
Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han participado en protocolos de Roche anteriores.An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS®) as monotherapy or in combination with ribavirin (COPEGUS®) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocolsChronic hepatitis CHepatitis C crónicaMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-002022-10-ESF. Hoffmann-La Roche Ltd